Literature DB >> 23348423

The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.

Xiu Fen Liu1, David J FitzGerald, Ira Pastan.   

Abstract

SS1P is a recombinant immunotoxin composed of an antimesothelin Fv fragment fused to a truncated portion of Pseudomonas exotoxin A. SS1P targets and kills mesothelin-expressing tumors, which include mesothlioma as well as ovarian, lung, and pancreatic cancers. SS1P is currently in clinical trials in mesothelioma. Because insulin acting through the insulin receptor is a survival factor for many cancer cell lines, we explored how lowering insulin receptor level would affect the cytotoxic action of SS1P. We show here that siRNA knockdown of the insulin receptor enhanced the cytotoxic action of native Pseudomonas exotoxin and enhanced SS1P toxicity on several human cell lines, but did not affect the response to other cytotoxic agents such as TRAIL, etoposide, and cycloheximide. To determine how insulin receptor knockdown enhances SS1P action, we analyzed various steps involved in cell killing. We found that insulin receptor knockdown increases the cleavage of SS1P by furin, which allows more toxin to reach the cytosol and inactivate elongation factor 2. These findings indicate that the insulin receptor negatively regulates immunotoxin action. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348423      PMCID: PMC3618569          DOI: 10.1158/0008-5472.CAN-12-3436

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism.

Authors:  L Sciacca; A Costantino; G Pandini; R Mineo; F Frasca; P Scalia; P Sbraccia; I D Goldfine; R Vigneri; A Belfiore
Journal:  Oncogene       Date:  1999-04-15       Impact factor: 9.867

Review 2.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 3.  Arming antibodies: prospects and challenges for immunoconjugates.

Authors:  Anna M Wu; Peter D Senter
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

Review 4.  Immunotoxin therapy of cancer.

Authors:  Ira Pastan; Raffit Hassan; David J Fitzgerald; Robert J Kreitman
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

Review 5.  Critical nodes in signalling pathways: insights into insulin action.

Authors:  Cullen M Taniguchi; Brice Emanuelli; C Ronald Kahn
Journal:  Nat Rev Mol Cell Biol       Date:  2006-02       Impact factor: 94.444

6.  Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.

Authors:  Raffit Hassan; Zoltan G Laszik; Megan Lerner; Mark Raffeld; Russell Postier; Daniel Brackett
Journal:  Am J Clin Pathol       Date:  2005-12       Impact factor: 2.493

7.  Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins.

Authors:  M F Chiron; C M Fryling; D FitzGerald
Journal:  J Biol Chem       Date:  1997-12-12       Impact factor: 5.157

8.  Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.

Authors:  Raffit Hassan; Susie Bullock; Ahalya Premkumar; Robert J Kreitman; Hedy Kindler; Mark C Willingham; Ira Pastan
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

Review 9.  Mesothelin targeted cancer immunotherapy.

Authors:  Raffit Hassan; Mitchell Ho
Journal:  Eur J Cancer       Date:  2007-10-22       Impact factor: 9.162

Review 10.  Mesothelin: a new target for immunotherapy.

Authors:  Raffit Hassan; Tapan Bera; Ira Pastan
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

View more
  13 in total

1.  Actinomycin D enhances killing of cancer cells by immunotoxin RG7787 through activation of the extrinsic pathway of apoptosis.

Authors:  Xiu Fen Liu; Laiman Xiang; Qi Zhou; Jean-Philippe Carralot; Marco Prunotto; Gerhard Niederfellner; Ira Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-06       Impact factor: 11.205

2.  Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo.

Authors:  Katja Spiess; Mads G Jeppesen; Mikkel Malmgaard-Clausen; Karen Krzywkowski; Kalpana Dulal; Tong Cheng; Gertrud M Hjortø; Olav Larsen; John S Burg; Michael A Jarvis; K Christopher Garcia; Hua Zhu; Thomas N Kledal; Mette M Rosenkilde
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-15       Impact factor: 11.205

3.  Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.

Authors:  Prince Awuah; Tapan K Bera; Messan Folivi; Oleg Chertov; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-05-18       Impact factor: 6.261

4.  Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.

Authors:  Xiufen Liu; Fabian Müller; Alan S Wayne; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

5.  Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.

Authors:  Xiu-Fen Liu; Laiman Xiang; David J FitzGerald; Ira Pastan
Journal:  Mol Cancer Ther       Date:  2013-10-21       Impact factor: 6.261

6.  Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design.

Authors:  Fabian Müller; Tyler Cunningham; Xiu Fen Liu; Alan S Wayne; Ira Pastan
Journal:  Clin Cancer Res       Date:  2016-04-25       Impact factor: 12.531

7.  Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.

Authors:  Fatima Ali-Rahmani; David J FitzGerald; Scott Martin; Paresma Patel; Marco Prunotto; Pinar Ormanoglu; Craig Thomas; Ira Pastan
Journal:  Cancer Res       Date:  2015-12-30       Impact factor: 13.312

Review 8.  Immunotoxins: the role of the toxin.

Authors:  Antonella Antignani; David Fitzgerald
Journal:  Toxins (Basel)       Date:  2013-08-21       Impact factor: 4.546

9.  Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.

Authors:  Abid R Mattoo; Ira Pastan; David Fitzgerald
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

10.  Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway.

Authors:  Xiu-Fen Liu; Qi Zhou; Raffit Hassan; Ira Pastan
Journal:  Oncotarget       Date:  2017-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.